WO2000027377A3 - Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen - Google Patents

Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen Download PDF

Info

Publication number
WO2000027377A3
WO2000027377A3 PCT/EP1999/008181 EP9908181W WO0027377A3 WO 2000027377 A3 WO2000027377 A3 WO 2000027377A3 EP 9908181 W EP9908181 W EP 9908181W WO 0027377 A3 WO0027377 A3 WO 0027377A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
peptide analogs
fibrotic disorders
phosphinate
phosphinate peptide
Prior art date
Application number
PCT/EP1999/008181
Other languages
English (en)
French (fr)
Other versions
WO2000027377A2 (de
Inventor
Elmar-Reinhold Burchardt
Michael Schauer
Walter Stoecker
Thomas Lampe
Original Assignee
Bayer Ag
Burchardt Elmar Reinhold
Michael Schauer
Walter Stoecker
Thomas Lampe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Burchardt Elmar Reinhold, Michael Schauer, Walter Stoecker, Thomas Lampe filed Critical Bayer Ag
Priority to AU31481/00A priority Critical patent/AU3148100A/en
Priority to US09/830,741 priority patent/US6750202B1/en
Priority to JP2000580606A priority patent/JP2002529403A/ja
Priority to EP99969897A priority patent/EP1124845A2/de
Priority to CA002348934A priority patent/CA2348934A1/en
Publication of WO2000027377A2 publication Critical patent/WO2000027377A2/de
Publication of WO2000027377A3 publication Critical patent/WO2000027377A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Phosphinat-Peptidanaloga der allgemeinen Formel (I) als Inhibitoren der Procollagen-C-Proteinase (PCP) zur Behandlung fibrotischer Erkrankungen.
PCT/EP1999/008181 1998-10-30 1999-10-28 Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen WO2000027377A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU31481/00A AU3148100A (en) 1998-10-30 1999-10-28 Phosphinate peptide analogs for the treatment of fibrotic disorders
US09/830,741 US6750202B1 (en) 1998-10-30 1999-10-28 Phosphinate peptide analogs for the treatment of fibrotic disorders
JP2000580606A JP2002529403A (ja) 1998-10-30 1999-10-28 線維性疾患の処置のためのホスフィネートペプチド類縁体
EP99969897A EP1124845A2 (de) 1998-10-30 1999-10-28 Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen
CA002348934A CA2348934A1 (en) 1998-10-30 1999-10-28 Phosphinate peptide analogs for the treatment of fibrotic disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19850072.6 1998-10-30
DE19850072A DE19850072A1 (de) 1998-10-30 1998-10-30 Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen

Publications (2)

Publication Number Publication Date
WO2000027377A2 WO2000027377A2 (de) 2000-05-18
WO2000027377A3 true WO2000027377A3 (de) 2000-11-16

Family

ID=7886165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008181 WO2000027377A2 (de) 1998-10-30 1999-10-28 Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen

Country Status (7)

Country Link
US (1) US6750202B1 (de)
EP (1) EP1124845A2 (de)
JP (1) JP2002529403A (de)
AU (1) AU3148100A (de)
CA (1) CA2348934A1 (de)
DE (1) DE19850072A1 (de)
WO (1) WO2000027377A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053870A1 (de) * 2000-10-31 2002-05-08 Burchardt Elmar Reinhold Procollagen (III)-Propeptide und verwandte Substanzen zur Behandlung von fibrotischen Erkrankungen
DE10134243A1 (de) * 2001-07-14 2003-03-27 Burchardt Elmar Reinhold Phosphimat-Peptidanalyse zur Behandlung von fibrotischen Erkrankungen
KR20160106684A (ko) * 2014-01-10 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 히드록시포름아미드 유도체 및 그의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008853A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company Phosphinic acid amides as matrix metalloprotease inhibitors
EP0854191A2 (de) * 1997-01-02 1998-07-22 Smithkline Beecham Corporation Human cardiac/gehirn tolloid-ähnliches Protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008853A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company Phosphinic acid amides as matrix metalloprotease inhibitors
EP0854191A2 (de) * 1997-01-02 1998-07-22 Smithkline Beecham Corporation Human cardiac/gehirn tolloid-ähnliches Protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOND J S ET AL: "The astacin family of metalloendopeptidases", PROTEIN SCIENCE,GB,CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, vol. 4, no. 7, July 1995 (1995-07-01), pages 1247 - 1261-1261, XP002111749, ISSN: 0961-8368 *
FILE 'HOME' AT 17 10 49 ON 17 MAY 2000: "PROTECTION OF THE HYDROXYPHOSPHINYL FUNCTION OF PHOSPHINIC DIPEPTIDES BY ADAMANTYL APPLICATION TO THE SOLID-PHASE SYNTHESIS OF PHOSPHINIC PEPTIDES", J ORG CHEM (1996) 61(19) 6601-6605, XP002137994 *
YIALLOUROS I ET AL.: "PHOSPHINIC PEPTIDES THE FIRST POTENT INHIBITORS OF ASTACIN BEHAVE AS EXTREMELY SLOW-BINDING INHIBITORS", BIOCHEMICAL JOURNAL (1998 APR 15) 331 ( PT 2) 375-9, XP002137993 *

Also Published As

Publication number Publication date
JP2002529403A (ja) 2002-09-10
CA2348934A1 (en) 2000-05-18
AU3148100A (en) 2000-05-29
DE19850072A1 (de) 2000-05-04
EP1124845A2 (de) 2001-08-22
WO2000027377A2 (de) 2000-05-18
US6750202B1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
DE60329001D1 (en) 8-hydroxychinolinderivate
EP1602370A3 (de) Synergistische Kombinationen enthaltend einen Renininhibitor für kardiovaskulären Erkrankungen
BG106585A (en) Kinase inhibitors as therapeutic agents
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
CY2538B1 (en) Tetrahydropyrido compounds
IN2005KO00312A (de)
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
NZ503308A (en) Alpha-ketoamide multicatalytic protease inhibitors
AU1044500A (en) Imidazonaphthyridines
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
AU1022999A (en) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
EP1019047A4 (de) Antithrombotische mittel
MXPA04005809A (es) Inhibidores de proteinas quinasas.
HK1057886A1 (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
WO2000027377A3 (de) Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen
WO2003072537A3 (en) Selective protein tyrosine phosphatatase inhibitors
PT1651596E (pt) Novos derivados de 4,4?-ditiobis-(3-aminobutano-1-sulfonatos) e composições que os contêm
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
WO2003091243A8 (en) Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
MXPA03005400A (es) Metodo para preparacion de 11 (12)-pentadecen-15-olidos.
ATE366742T1 (de) Phosphinat-peptidanaloga als inhibitoren der procollagen-c-proteinase (pcp) zur behandlung von fibrotischen erkrankungen
WO2000034295A3 (en) Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
WO2000031092A3 (en) Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
WO2000031100A3 (en) Benzylmaltosides as inhibitors of smooth muscle cell proliferation
AU2002325155A1 (en) Phosphinate-peptide analogues as inhibitors of procollagen-c-proteinase (pcp) for treating fibrotic diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999969897

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2348934

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 580606

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2348934

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09830741

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999969897

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642